Updated On: 27 November, 2020 01:37 PM IST | Moscow | IANS
The parties intend to start the production of Sputnik V at the beginning of 2021

Photo used for representational purpose
The Russian Direct Investment Fund (RDIF) and Hetero, one of India's generic pharmaceutical companies, have agreed to produce in India over 100 million doses per year of Sputnik V Covid-19 vaccine in India.
The parties intend to start the production of Sputnik V at the beginning of 2021.